Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Laminin α1 is a genetic modifier of TGF-β1–stimulated pulmonary fibrosis
Chang-Min Lee, … , Chun Geun Lee, Jack A. Elias
Chang-Min Lee, … , Chun Geun Lee, Jack A. Elias
Published September 20, 2018
Citation Information: JCI Insight. 2018;3(18):e99574. https://doi.org/10.1172/jci.insight.99574.
View: Text | PDF
Research Article Pulmonology

Laminin α1 is a genetic modifier of TGF-β1–stimulated pulmonary fibrosis

  • Text
  • PDF
Abstract

The pathogenetic mechanisms underlying the pathologic fibrosis in diseases such as idiopathic pulmonary fibrosis (IPF) are poorly understood. To identify genetic factors affecting susceptibility to IPF, we analyzed a murine genetic model of IPF in which a profibrotic cytokine (TGF-β1) was expressed in the lungs of 10 different inbred mouse strains. Surprisingly, the extent of TGF-β1–induced lung fibrosis was highly strain dependent. Haplotype-based computational genetic analysis and gene expression profiling of lung tissue obtained from fibrosis-susceptible and -resistant strains identified laminin α1 (Lama1) as a genetic modifier for susceptibility to IPF. Subsequent studies demonstrated that Lama1 plays an important role in multiple processes that affect the pulmonary response to lung injury and susceptibility to fibrosis, which include: macrophage activation, fibroblast proliferation, myofibroblast transformation, and the production of extracellular matrix. Also, Lama1 mRNA expression was significantly increased in lung tissue obtained from IPF patients. These studies identify Lama1 as the genetic modifier of TGF-β1 effector responses that significantly affects the development of pulmonary fibrosis.

Authors

Chang-Min Lee, Soo Jung Cho, Won-Kyung Cho, Jin Wook Park, Jae-Hyun Lee, Augustine M. Choi, Ivan O. Rosas, Ming Zheng, Gary Peltz, Chun Geun Lee, Jack A. Elias

×

Figure 6

Increased expression of Lama1 in lungs from IPF patients.

Options: View larger image (or click on image) Download as PowerPoint
Increased expression of Lama1 in lungs from IPF patients.
(A) Levels of ...
(A) Levels of mRNA encoding Lama1 were evaluated, using qRT-PCR, in lung tissues from normal controls, patients with COPD, and patients with IPF. (B) Representative IHC staining of Lama1 in the lungs from controls and patients with IPF and COPD. Arrows indicate Lama1+ cells. Yellow arrows, fibroblasts-like cells; green arrows, macrophage-like cells. (C) Representative double IHC staining using macrophage- (CD68) and fibroblast-specific markers with Lama1 in lungs from IPF patients. *P < 0.05. Scale bars in B and C: 50 μm.

Copyright © 2022 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts